<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508609</url>
  </required_header>
  <id_info>
    <org_study_id>CLBS14-P01</org_study_id>
    <secondary_id>1R44HL135889-01</secondary_id>
    <nct_id>NCT03508609</nct_id>
  </id_info>
  <brief_title>Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease</brief_title>
  <official_title>An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caladrius Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Caladrius Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo
      selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with
      no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary
      infusion of CLBS14.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in coronary flow reserve</measure>
    <time_frame>Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in microvascular function as assessed by intracoronary administration of acetylcholine and nitroglycerin</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peripheral arterial tonometry</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with adverse events</measure>
    <time_frame>Day 365</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Microvascular Dysfunction</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLBS14</intervention_name>
    <description>GCSF-mobilized autologous CD34 cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age â‰¥18

          -  History of and currently experiencing angina at least 3 times per week

          -  No obstructive coronary artery disease

          -  On stable medical therapy for 30 days prior to enrollment

          -  Must agree to use a reliable and acceptable method of contraception for the duration
             of participation

          -  Written informed consent

        Exclusion Criteria:

          -  Myocardial infarction within 90 days

          -  Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or
             CABG)

          -  Diagnosis of other specific cardiac disease

          -  Must meet LVEF and GFR requirements

          -  Current use of coumadin or DOACs

          -  Hypersensitivity to G-CSF, apheresis or study product components

          -  Positive for HIV, hepatitis B or hepatitis C

          -  Active inflammatory or autoimmune disease, or chronic immunosuppressive state

          -  Drug abuse

          -  Pregnant or lactating

          -  Malignant neoplasm within 5 years

          -  History of Sickle Cell Disease

          -  Participation in another clinical study within 90 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas W. Losordo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrissy Kotynski</last_name>
    <phone>(908) 842-0093</phone>
    <email>ckotynski@caladrius.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Volk</last_name>
    <phone>(949) 346-8784</phone>
    <email>svolk@caladrius.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Joung</last_name>
      <phone>310-423-9666</phone>
      <email>sandy.joung@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Tracey Early</last_name>
      <phone>310-423-1231</phone>
      <email>Tracey.Early@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C. Noel Bairey Merz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Ryberg, RN</last_name>
      <phone>507-266-4095</phone>
      <email>hansonryberg.diane@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alysha Bleifus</last_name>
      <phone>507-255-7142</phone>
      <email>Bleifus.Alysha@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amir Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

